First-line chemotherapy of advanced or metastatic breast cancer (MBC) with docetaxel and doxorubicin in Indonesia: results from A phase II trial

Doxorubicin and docetaxel as a single agent are known as active cytotoxic agents for the treatment of metastatic breast cancer (MBC). Their combination has also shown to be highly active as a second-line chemotherapy of MBC. This study was design to evaluate the efficacy and safety of docetaxel-doxorubicin combination as first line chemotherapy of MBC patients in Indonesia. Twenty-six female patients between 31-65 years old with advanced or MBC was enrolled. No prior taxane or cumulative doxorubicin of 250 mg/m2 was allowed and patients should not have a heart disease. Treatment consisted of doxorubicin 50 mg/m2 as intravenous (IV) bolus followed one hour later by docetaxel 60 mg/m2 by IV infusion over 1 hour every 3 weeks for 6 cycles. Premedication with oral corticosteroid was administered a day prior to chemotherapy until the second day of each cycle. Left ventricular ejection fraction was recorded at baseline and after the 6th cycle. At the end of study, a total of 156 cycles of chemotherapy have been delivered.  Five and 11 patients had a complete response (CR) and partial response (PR), respectively, which accounted for a 61.54% best overall response. Three patients with extensive liver metastases showed complete disappearance after 6 cycles. Most frequent grade 3-4 toxicities were leukopenia (80.77%) and febrile neutropenia (5.77%). Leukopenia was usually short in duration, occurred mainly during the first and second cycle and did not require dose reduction. No patient developed heart failure. There was one death due to progressive disease after 6 cycles. Combination of doxorubicin 50 mg/m2 and docetaxel 60 mg/m2 was sufficiently active as first-line chemotherapy of MBC, especially in patients with liver metastases, with a manageable toxicity profile. (Med J Indones 2005; 14: 20-5) Keywords: docetaxel, doxorubicin, advanced or metastatic breast cancer, phase II trial, anthracycline and taxane combinatio

The relationship between menopausal status and different histopathological pictures among 300 Indonesian females with breast cancer

[no abstract available

Breast cancer case control study: Conceptual framework and epidemiological study design

Suatu penelitian kanker payudara secara multi disipliner telah dilaksanakan di Rumah Sakit Umum Pusat Nasional Dr.Cipto Mangunkusumo Jakarta dari lahun 1988 sampai tahun 1991. Bagian studi epidemiologi dari proyek ini mempergunakan disain Case'Control dalam upaya penilaian pengaruh berbagai faktor kausal untuk kejadian kanker payudara di kalangan wanita Indonesia. Berdasarkan hasil penelitian sebelumnya maupun literatur yang ada, telah disusun suatu konsep yang spesifik bagi penelitian ini. Kerangka konsep penelitian ini menyoroti hubunganyang diperkirakan ada dalam perkembangan kanker payudara dengai fahor-fahor berikut: 7) keturunan genetik dalam keluarga, 2) pajanan hormonal, baik intrinsik maupun ekstrinsik, i) penumpukai lemaktubuh, 41 trauma dan pajanan langsung lainnya atas jaringan payudara, 5) pota hidup yang spesifik. Penelitian ini melibatkan 300 kasus baru kanker payudara dan 600 kontrol serasi yang dipitih dari pengunjung bukan tumor d.i RSCM pada periode waktu yang sama. Faktor penentu keserasian kontrol adalah kelompok usia dan status sosial ekonom

Comparative epidemiological analysis on two-batch study of breast cancer in Dr. Cipto Mangunkusumo Hospital, Jakarta - Indonesia

[no abstract available

Erratum: Comparative epidemiological analysis on two-batch study of breast cancer in Dr. Cipto Mangunkusumo Hospital, Jakarta - Indonesia

[This corrects the article DOI: 10.13181/mji.v8i2.682

Pathological aspects of breast cancer in Indonesian females, emphasizing on the modified W.H.O. classifïcation

[no abstract available

Clinicopathology profile evaluated against several risk factors in breast cancer cases

<span>[no abstract available]</span

Risk factors in the development of breast cancer among Indonesian women

[no abstract available